Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma
ASCO Calls On NCI To Double Funding For Cooperative Group Clinical Trials
Tasigna Shows Benefit Over Gleevec In Phase III Study for Ph+ CML In Chronic Phase
Bosutinib Vs. Imatinib Study Didn’t Meet Primary Endpoint
Autologous BMT Equivalent To Allogeneic For Myeloma
Non-Adherence To Protocol Explains Outcome Differences In Hispanic Children With ALL
Afinitor Delayed Progression Compared To Tamoxifen Alone In Randomized Phase II Study
AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III
Survival For ALL Increased To 94 Percent In Recent Years
TTF Increased Survival Compared To Chemotherapy
Randomized Trial Finds Sunscreen Use Cuts Risk Of Developing Melanoma
Clinical Trials Approved By NCI CTEP Last Month
Trending Stories
- The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear” - How MD Anderson and Texas Children’s made plans to build a $1 billion pediatric cancer hospital—one of the world’s largest
- In the Headlines: MD Anderson’s Pisters on doing “something gigantic for pediatric cancer”
- As cancer scientists, we must change how we engage with the public on the impact of NIH cuts
What the scientific method obscures - In weekly vigils, current and former NIH staff grieve the impact of Trump cuts
The Saturday gatherings at NIH’s Metro station are part graveside service, part street theater - Scaling excellence: How City of Hope is transforming cancer care delivery